Circulating TNFSF14 (Tumor Necrosis Factor Superfamily 14) Predicts Clinical Outcome in Patients with Stable Coronary Artery Disease
Journal
Arteriosclerosis, Thrombosis, and Vascular Biology
Journal Volume
39
Journal Issue
6
Pages
1240-1252
Date Issued
2019
Author(s)
Hsu C.-Y.
Tseng W.-K.
Lin T.-H.
Yeh H.-I.
Chang K.-C.
Wang J.-H.
Chou R.-H.
Huang C.-Y.
Huang P.-H.
Leu H.-B.
Yin W.-H.
Lin S.-J.
Chen J.-W.
Abstract
Objective-Basic research indicates that TNFSF14 (tumor necrosis factor superfamily 14) may be involved in the pathogenesis of atherosclerosis. Given the requirements of new biomarkers for risk classification in coronary artery disease (CAD), we conducted a longitudinal analysis to investigate if TNFSF14 levels are associated with the risk of cardiovascular events among patients with stable CAD. Approach and Results-In total, 894 patients with CAD were enrolled in a multicenter prospective study. The primary outcome was the occurrence of cardiovascular death, nonfatal myocardial infarction, and stroke. The secondary outcome was the occurrence of all-cause death, nonfatal myocardial infarction, stroke, revascularization, and hospitalization because of angina or heart failure. During the mean follow-up period of 22±9 months, 32 patients reached the primary outcome and 166 patients reached the secondary outcome. Kaplan-Meier analysis showed that the event-free survival was significantly different in the first and fourth quartile groups in subjects categorized by TNFSF14 levels. In multivariate Cox proportional hazard regression analysis, TNFSF14 was independently associated with the risk of cardiovascular events after adjustment for various relevant factors (adjusted hazard ratio, 1.14; 95% CI, 1.04-1.25). In the validation cohort of 126 multivessel patients with CAD, TNFSF14 was confirmed to provide good prognostic predictive value for composite cardiovascular events (adjusted hazard ratio, 1.11; 95% CI, 1.04-1.19). Conclusions-This is the first study to demonstrate that increased TNFSF14 levels were independently associated with the occurrence of cardiovascular events in patients with stable CAD. Future studies are worthy to validate if TNFSF14 could be a novel prognostic biomarker for CAD outcomes over different populations. ? 2019 ? 2019 American Heart Association, Inc. All rights reserved.
SDGs
Other Subjects
adiponectin; amino terminal pro brain natriuretic peptide; biological marker; cytokine; gelatinase B; interleukin 6; tumor necrosis factor; tumor necrosis factor superfamily 14; unclassified drug; biological marker; herpesvirus entry mediator ligand; TNFSF14 protein, human; adult; all cause mortality; Article; cardiovascular mortality; cardiovascular risk; cerebrovascular accident; clinical outcome; cohort analysis; coronary artery disease; electrocardiogram; event free survival; female; follow up; heart infarction; heart muscle revascularization; hospitalization; human; Kaplan Meier method; laboratory test; major clinical study; male; middle aged; multicenter study; observational study; outcome assessment; predictive value; priority journal; prospective study; protein blood level; aged; blood; cause of death; clinical trial; coronary artery disease; disease exacerbation; epidemiology; incidence; longitudinal study; mortality; risk assessment; risk factor; Taiwan; time factor; upregulation; very elderly; Aged; Aged, 80 and over; Biomarkers; Cause of Death; Coronary Artery Disease; Disease Progression; Female; Hospitalization; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Progression-Free Survival; Prospective Studies; Risk Assessment; Risk Factors; Stroke; Taiwan; Time Factors; Tumor Necrosis Factor Ligand Superfamily Member 14; Up-Regulation
Publisher
Lippincott Williams and Wilkins
Type
journal article